Octant Began Clinical Trial for Retinitis Pigmentosa Drug
The biotech firm has dosed its first patient in a mid-stage trial for an oral treatment targeting RHO-adRP.
Updated on Sept. 25, 2026 in Biotech
Live Poll
Should medical research prioritize developing new drug treatments for rare diseases?
Drug discovery company Octant has initiated the Phase 1b/2 clinical trial for its investigational oral small molecule, OCT-980. This study marks a significant step for patients with RHO-adRP, a rare inherited retinal disease that currently lacks any approved treatments.
Why it matters
The trial aims to address the root cause of protein dysfunction in patients with RHO-adRP by stabilizing misfolded rhodopsin. Researchers are investigating whether this approach can restore cellular trafficking, improve low-light vision, and effectively halt disease progression.
The clinical trial is officially tracked under registration identifier NCT07408232. The study is designed to measure safety, tolerability, pharmacokinetics, and pharmacodynamics of the oral molecule.
The players
Octant
Octant is a drug discovery company headquartered in Emeryville, California.
The details
OCT-980 functions by stabilizing misfolded rhodopsin proteins to restore normal cellular activity within the eye. This multi-center study represents the transition from testing on healthy volunteers in Phase 1a to evaluating clinical outcomes in patients suffering from the disease.
Timeline
September 25, 2026: Octant announced that the first patient had received a dose of the study drug.
The Big Picture
This development follows the research protocols established in the clinical study information for NCT07408232. This study reflects a broader paradigm shift toward molecular-level stabilization as a primary strategy for treating previously incurable inherited degenerative diseases.
While the trial is currently in the investigational phase, patients with RHO-adRP may eventually gain access to the first-ever pharmacological treatment for their condition. The trial outcomes will determine if this oral medication provides a viable, non-invasive alternative to managing progressive vision loss.
The takeaway
The initiation of this trial signals a hopeful shift toward addressing the genetic mechanisms of retinal degeneration rather than just managing symptoms. Patients and clinicians should monitor further updates from the study for evidence regarding the drug's impact on visual function.
Further reading
For more on the latest research in this sector, visit Biotech.
More information
View full details regarding the study protocol via the clinical study information portal.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Should medical research prioritize developing new drug treatments for rare diseases?
